THEODORE MARTIN PAGE
Pilots at Lighthouse Rd, Carlsbad, CA
License number
California A2276981
Issued Date
Aug 2015
Expiration Date
Aug 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
1045 Lighthouse Rd, Carlsbad, CA 92011
Personal information
See more information about THEODORE MARTIN PAGE at radaris.comName
Address
Phone
1045 Lighthouse Rd, Carlsbad, CA 92011
4308 Sea Bright Dr, Carlsbad, CA 92008
6071 Knoll Park Ct, San Jose, CA 95120
35783 Avocado St, Yucaipa, CA 92399
2300 E Valley Pkwy SPC 53, Escondido, CA 92027
Professional information
Uridine Therapy For Patients With Elevated Purine Levels
US Patent:
6727231, Apr 27, 2004
Filed:
Oct 12, 2000
Appl. No.:
09/689551
Inventors:
Theodore M. Page - Carlsbad CA
Deborah Brewer - Bethesda MA
Charles D. Moseley - Arlington VA
Deborah Brewer - Bethesda MA
Charles D. Moseley - Arlington VA
Assignee:
Repligen Corporation - Needham MA
International Classification:
A01N 4304
US Classification:
514 50, 514 49, 536 285, 536 2853
Abstract:
The invention is based on the discovery that patients having elevated purine levels, e. g. , individuals diagnosed with pervasive developmental disorders, such as autistic disorder, and/or neuromuscular disorders, can be treated with uridine compositions.
Therapeutic Treatment Methods 2
US Patent:
2005010, May 12, 2005
Filed:
Dec 5, 2003
Appl. No.:
10/728400
Inventors:
Christopher Reading - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
International Classification:
A61K031/57
US Classification:
514178000
Abstract:
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Sepsis Treatment Methods
US Patent:
2007021, Sep 13, 2007
Filed:
Oct 16, 2006
Appl. No.:
11/549875
Inventors:
Christopher Reading - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - Carlsbad CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - Carlsbad CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
International Classification:
A61K 31/56, A61K 31/58
US Classification:
514178000, 514169000, 514172000
Abstract:
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3η-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Asthma Treatment Methods
US Patent:
2007026, Nov 15, 2007
Filed:
Oct 16, 2006
Appl. No.:
11/549825
Inventors:
Christopher Reading - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
International Classification:
A61K 31/56, A61P 11/06
US Classification:
514172000, 514169000
Abstract:
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Therapeutic Treatment Methods
US Patent:
2007027, Nov 29, 2007
Filed:
Feb 12, 2007
Appl. No.:
11/674126
Inventors:
Christopher Reading - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
International Classification:
A61K 31/58, A61P 19/02, A61K 31/56
US Classification:
514169000, 514178000, 514176000
Abstract:
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Disease Treatment Methods
US Patent:
2008008, Apr 10, 2008
Filed:
Oct 13, 2006
Appl. No.:
11/549615
Inventors:
Christopher L. Reading - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - Escondido CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore M. Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - Escondido CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore M. Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Assignee:
Hollis-Eden Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/58, A61P 17/06, A61P 3/10, A61P 43/00
US Classification:
514176
Abstract:
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α, 17β-trihydroxyandrostane.
Cystic Fibrosis Treatment Methods
US Patent:
2008009, Apr 17, 2008
Filed:
Oct 13, 2006
Appl. No.:
11/549580
Inventors:
Christopher L. Reading - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - Sand Diego CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - Sand Diego CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Assignee:
Hollis-Eden Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/58, A61K 31/56, A61P 43/00
US Classification:
514173, 514169, 514172, 514176
Abstract:
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Therapeutic Treatment Methods
US Patent:
7547687, Jun 16, 2009
Filed:
Feb 12, 2007
Appl. No.:
11/674128
Inventors:
Christopher L. Reading - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - Carlsbad CA, US
Mei Li - San Diego CA, US
Theodore M. Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Clarence N. Ahlem - San Diego CA, US
Dominick L. Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James M. Frincke - Carlsbad CA, US
Mei Li - San Diego CA, US
Theodore M. Page - Carlsbad CA, US
Dwight R. Stickney - Granite Bay CA, US
Richard J. Trauger - Leucadia CA, US
Steven K. White - San Diego CA, US
Assignee:
Hollis-Eden Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/568
US Classification:
514169, 514176
Abstract:
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
Therapeutic Treatment Methods
US Patent:
2004013, Jul 15, 2004
Filed:
Aug 28, 2003
Appl. No.:
10/651515
Inventors:
Christopher Reading - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
Clarence Ahlem - San Diego CA, US
Dominick Auci - San Diego CA, US
Charles Dowding - San Diego CA, US
James Frincke - San Diego CA, US
Mei Li - San Diego CA, US
Theodore Page - Carlsbad CA, US
Dwight Stickney - Granite Bay CA, US
Richard Trauger - Leucadia CA, US
Steven White - San Diego CA, US
International Classification:
A61K031/56
US Classification:
514/169000
Abstract:
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3-hydroxy-17-aminoandrost-5-ene, 3-hydroxy-16-fluoro-17-aminoandrost-5-ene, 3-hydroxy-16-fluoro-17-aminoandrost-5-ene, 3-hydroxy-16-fluoro-17-aminoandrost-5-ene, 1,3-dihydroxy-4-fluoroandrost-5-ene-17-one, 1,3,17-trihydroxy-4-fluoroandrost-5-ene, 1,3-dihydroxy-6-bromoandrost-5-ene, 1-fluoro-3,12-dihydroxyandrost-5-ene-17-one, 1-fluoro-3,4-dihydroxyandrost-5-ene and 4-fluoro-3,6,17-trihydroxyandrostane.